# US 2023/0272071 A1 · Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272071 A1
- Document ID: US20230272071A1
- Status: Published application
- Kind: A1
- Application number: 18/006,698
- Filed: 2021-07-26
- Published: 2023-08-31
- Earliest claimed: 2020-07-27
- Assignees: Arizona Board of Regents on Behalf of the University of Arizona
- Applicants: Arizona Board of Regents On Behalf of the University of Arizona
- Inventors: Michael S. KUHNS; Mark S. LEE; Deepta BHATTACHARYA
- Web page: https://patentgrep.com/patent/US20230272071A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C07K 2317/35: Valency
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are nucleotide and polypeptide sequences of alternative immunoglobulin domains, engineered to create non-native N′- and C′-termini in the loop regions of the three-dimensional β-sheet structure of the domain, for use as fusion partners with additional polypeptide sequences. Such polypeptides can be used as reagents, research tools, or therapeutics.

## Claims

### Claim 1

A nucleotide sequence encoding a polypeptide, where the polypeptide comprises one or more immunoglobulin domains comprising a fusion of the wild type N- and C-termini or an optional a linker joining the wild type N- and C-termini and a scission within one of the loop regions yielding novel N′- and C′-termini.

### Claim 2 (depends on 1)

The nucleotide sequence of claim 1, wherein the immunoglobulin domain comprises an immunoglobulin domain from an immunoglobulin, Fab, Fv, T cell receptor (TCR), CD80, CTLA-4, PD1, PDL1, MHC molecules, or other immunoglobulin domain containing proteins.

### Claim 3 (depends on 1, 2)

The nucleotide sequence of claim 1 or 2, wherein the immunoglobulin domain comprises a heavy chain variable domain or a light chain variable domain.

### Claim 4 (depends on 1, 2, 3)

The nucleotide sequence of any one of claims 1-3, wherein one or both of the N′- and C′-termini are fused with one or more additional polypeptides.

### Claim 5 (depends on 1, 2, 3, 4)

The nucleotide sequence of any one of claims 1-4, wherein the additional polypeptide comprises an immunoglobulin domain, Fab, Fv, ScFV, cell receptor, pMHC, costimulatory molecule, cytokine, or another polypeptide domain.

### Claim 6 (depends on 1, 2, 3, 4)

The nucleotide sequence of any one of claims 1-4, wherein the additional polypeptide comprises an immunoglobulin hinge region.

### Claim 7 (depends on 1, 2, 3, 4)

The nucleotide sequence of any one of claims 1-4, wherein the additional polypeptide comprises one or more of: CD80, CD86, ICAM-1, PD-L1/L2, B7H1, B7H2, CD40, CD40L, CD47, CD48, CD58, 4-1BBL, OX40L, TIM-1, TIM-4, CD80:PD-L1 heterodimer, calreticulin, a peptide that is at least 90% identical to CD80, CD86, ICAM-1, PD-L1/L2, B7H1, B7H2, CD40, CD40L, CD47, CD48, CD58, 4-1BBL, OX40L, TIM-1, TIM-4, CD80:PD-L1 heterodimer, calreticulin, fragments thereof, or combinations thereof; cytokines: IFNα, IFNβ, IFNγ, IL-1, IL-1α, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, IL-23, TNF, TNFα, TGFβ, GM-CSF, CSF-1, a peptide that is at least 90% identical to IFNα, IFNβ, IFNγ, IL-1, IL-1α, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, IL-23, TNF, TNFα, TGFβ, GM-CSF, CSF-1, fragments thereof, or combinations thereof; MHC alleles: MHC molecule comprises HLA-A, HLA-B, HLA-C, β2-microglobulin, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB β, H2-EKα, H2-EKβ, a peptide that is at least 90% identical to HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB, H2-Aa, H2-B1, H2-K1, H2-EB β, H2-EKα, H2-EKβ, fragments thereof, or combinations thereof; or TCR molecules: TRAC, TRBC1, TRBC2, TRDC, TRGC1, TRGC2, TCRA, TCB1, TCB2, TCC1, TCC2, TCC3, TCC4, a peptide that is at least 90% identical to TRAC, TRBC1, TRBC2, TRDC, TRGC1, TRGC2, TCRA, TCB1, TCB2, TCC1, TCC2, TCC3, TCC4, fragments thereof, or combinations thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleotide sequence of any one of claims 1-7, wherein the optional linker comprises a polypeptide linker or a chemical linker.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The nucleotide sequence of any one of claims 1-8, wherein the I optional inker comprises a polypeptide selected from one or more of a poly glycine linker, poly alanine linker, poly glycine-alanine linker, poly glycine-serine linker, or poly glycine-serine-proline linker.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The nucleotide sequence of any one of claims 1-9, wherein the optional linker comprises a polypeptide having 85% to 99% identity to one or more of SEQ ID NO: 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleotide sequence of any one of claims 1-10, wherein the optional linker is a polypeptide selected from one or more of SEQ ID NO: 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The nucleotide sequence of any one of claims 1-11, wherein the loop region where scission occurs comprises one or more of the loops connecting adjacent β-strands comprising A-B, B-C, C-C′, C′-C″, C-D, C′-D, C″-D, D-E, E-F, F-G, or other loop-linkages that eliminate one or more intervening β-strands.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The nucleotide sequence of any one of claims 1-12, wherein the loop region where scission occurs comprises one or more of the immunoglobulin β-sheet loops A-B, B-C, C-C′, C′-C″, C-D, C′-D, C″-D, D-E, E-F, or F-G.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nucleotide sequence of any one of claims 1-13, wherein the loop region where scission occurs comprises the C-C′ or A-B loop.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The nucleotide sequence of any one of claims 1-14, wherein the nucleotide sequence has 85% to 99% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 33.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The nucleotide sequence of any one of claims 1-15, wherein the nucleotide sequence is selected from SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 33.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A polynucleotide vector comprising one or more nucleotide sequences of any one of claims 1-16.

### Claim 18 (depends on 1, 17)

A cell comprising one or more nucleotide sequences of claim 1 or a polynucleotide vector of claim 17.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A polypeptide encoded by the nucleotide sequence of any one of claims 1-16.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A polypeptide encoded by the nucleotide sequence of any one of claims 1-16, wherein the polypeptide has 85% to 99% identity to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A polypeptide encoded by the nucleotide sequence of any one of claims 1-16, wherein the polypeptide is selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34.

### Claim 22

A bivalent polypeptide complex comprising a dimer of the polypeptides of SEQ ID NO: 32 or 34 covalently linked via one or more disulfide bonds.

### Claim 23

A single chain variable fragment (scFv) polypeptide comprising SEQ ID NO: 34.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A process for manufacturing the nucleotide sequence of any one of claims 1-16 or a polypeptide encoded by the nucleotide sequence of any one of claims 1-16, the process comprising: transforming or transfecting a cell with the nucleic acid; growing the cells; optionally isolating additional quantities of the nucleotide sequence; inducing expression of the polypeptide; and isolating the polypeptide.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A means for manufacturing the nucleotide sequence of any one of claims 1-16 or a polypeptide encoded by the nucleotide sequence of any one of claims 1-16, the means comprising: transforming or transfecting a cell with the nucleic acid; growing the cells; optionally isolating additional quantities of the nucleotide sequence; inducing expression of the polypeptide; and isolating the polypeptide.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 21, 22)

The nucleotide sequence of any one of claims 1-16 or a polypeptide encoded by the nucleotide sequence of any one of claims 1-16 produced by the process of claim 21 or the means of claim 22.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of treatment comprising administering an effective amount of polypeptide encoded by the nucleotide sequence of any one of claims 1-16 to a subject in need thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of an effective amount of a polypeptide encoded by the nucleotide sequence of any one of claims 1-16 for the treatment of a disease or disorder comprising administering an effective amount the polypeptide to a subject in need thereof.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A research tool comprising a polypeptide encoded by the nucleotide sequence of any one of claims 1-16.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An immunochemical reagent comprising a polypeptide encoded by the nucleotide sequence of any one of claims 1-16.
